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Chromosomal translocations with breakpoints in T-cell recep-
tor (TCR) genes are recurrent in T-cell malignancies. These
translocations involve the TCRad gene (14q11), the TCRb gene
(7q34) and to a lesser extent the TCRc gene at chromosomal
band 7p14 and juxtapose T-cell oncogenes next to TCR
regulatory sequences leading to deregulated expression of
those oncogenes. Here, we describe a new recurrent chromo-
somal inversion of chromosome 7, inv(7)(p15q34), in a subset
of patients with T-cell acute lymphoblastic leukemia character-
ized by CD2 negative and CD4 positive, CD8 negative blasts.
This rearrangement juxtaposes the distal part of the HOXA gene
cluster on 7p15 to the TCRb locus on 7q34. Real time
quantitative PCR analysis for all HOXA genes revealed high
levels of HOXA10 and HOXA11 expression in all inv(7) positive
cases. This is the first report of a recurrent chromosome
rearrangement targeting the HOXA gene cluster in T-cell
malignancies resulting in deregulated HOXA gene expression
(particularly HOXA10 and HOXA11) and is in keeping with a
previous report suggesting HOXA deregulation in MLL-rear-
ranged T- and B cell lymphoblastic leukemia as the key factor in
leukaemic transformation. Finally, our observation also sup-
ports the previous suggested role of HOXA10 and HOXA11 in
normal thymocyte development.
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Introduction
T-cell acute lymphoblastic leukemia (T-ALL) represents 10–15%
of childhood and 25% of adult ALLs, and are associated with an
intermediate prognosis within the total group of ALLs.1 In T-ALL,
chromosomal rearrangements affecting the T-cell receptor loci
(TCR) were among the first to be detected. Similar to
translocations involving the IGH locus, these chromosomal
changes cause ectopic expression of target genes due to
juxtaposition to TCR gene enhancers. These pivotal studies
showed that T-ALLs were genetically very heterogeneous with
the most frequently detected translocation, the t(11;14)(p15;q11),
being found in less than 10% of cases.2 One particular rare
translocation, t(1;14)(p32;q11), lead to the discovery of the
TAL1(SCL) gene that turned out to be of crucial importance
in normal T-cell development. Most interestingly, TAL1(SCL)
was later shown to be transcriptionally activated due to a cryptic
90 kb interstitial deletion in as much as 20% of T-ALLs, thus
representing the most frequent genetic abnormality in this
disease.3 Similarly, other T-cell leukemia specific genes
(HOX11, LYL1, LMO1, LMO2, HOX11L2), initially identified
through rare chromosomal rearrangements involving TCR loci,
were also shown to be transcriptionally activated in T-ALLs
without evidence for particular translocations. Also, recent
studies showed biallelic overexpression of some of these genes
thus further supporting the notion for a broader implication in
T-ALL through mechanisms other than the known translocation
events.4 Furthermore, the unexpected finding of amplification of
a NUP214/ABL1 fusion gene in a minority of T-ALL patients,5,6
further illustrated the diversity of genetic events involved in
T-ALLs. Likewise, the NOTCH1 gene, involved in the
t(7;9)(q34;q34) in less than 1% of T-ALLs, was shown to harbor
activating mutations in more than 50% of T-ALLs.7
Although involvement of each of the three TCR loci in
recurrent chromosomal changes in T-ALL is well recognized,8
both the incidence and the exact contribution of each of
these loci in recurrent chromosome abnormalities have
not yet been assessed in detail. The finding of a previously
unreported t(7;11)(q34;q24) in a child with T-ALL, as the
result of a multicolor fluorescence in situ hybridization
(M-FISH) study on T-ALLs, prompted us to screen a large cohort
of 94 patients with T-ALL. This resulted in the finding of a new
recurrent chromosomal rearrangement, that is, a pericentric
inversion of chromosome 7, inv(7)(p15q34), in a subset of T-ALL
patients. This inversion was associated with an elevated
expression of HOXA10 and HOXA11, most probably due to
juxtaposition near strong enhancers embedded within the TCRb
locus. This is the second report providing evidence




Diagnostic bone marrow, peripheral blood or pleural fluid
samples from 49 adults and 45 children with T-ALL were
collected from three institutes, retrospectively. For 32 T-ALL
cases (16 children and 16 adults) frozen cells were available for
expression analysis. These selected cases contained all cases
positive for TCRb chromosomal rearrangement and 13 cases
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without TCRb rearrangement, which were investigated by FISH
(see below). Table 1 lists biological and cytogenetic findings for
these patients. Total child thymocyte suspension (CT) and
purified CD34þ thymus cells (CD34þ T) were isolated as
described before.9
Immunophenotyping
Immunophenotypic studies were carried out in the respective
centers according to established protocols. Cases were classified
using the European Group for the Immunological Characteriza-
tion of Leukemias (EGIL) recommendations.10 Briefly, EGIL T1
(pro-T ALL) was defined by the presence of only CD7, T2 (pre-T
ALL) by CD2 and/or CD5 and/or CD8 positivity, T3 (cortical
T-ALL) by CD1a positivity and T4 (mature T-ALL) by the
presence of surface CD3 and lack of CD1a.
Cytogenetic studies
The different diagnostic specimens (bone marrow, blood and
pleural fluid) were cultured and harvested for cytogenetic
analysis according to established methods. Chromosome slides
were G-, Q- or R-banded. Chromosome aberrations are
described according to guidelines of an International System
for Human Cytogenetic Nomenclature (ISCN 1995).11
Table 1 Biological characteristics and cytogenetic findings of TCRb positive (case n1 1–19; with identified partner gene) and negative T-ALL
patients (case n1 20–32)
Case
no.
Age Sex Karyotype TCRb partner
gene
Revised karyotype
1 4 M 46,XY, t(1;14)(p32;q11) [20] Unknown 46,XY, t(1;14)(p32;q11), t(6;10)(q25;q24),
t(7;11)(q34;q24)a
2 19 M 46, XY, t(1;7)(p32;q34), del(6)(q12q16) [14]/46, XY [1] TAL1 (1p32) 46, XY, t(1;7)(p32;q34), del(6)(q12q16)
[14]/46, XY [1]
3 45 M 46,XY [9] Unknown 46,XY, t(7;?)(q34;?) [9]
4 6 M 47,XY,+8,del(9)(p21) [3]/46,XY [8] Unknown 47,XY, t(7;?)(q34;?),+8, del(9)(p21)
[3] /46,XY [8]
5 12 F 46, XX,del(6)(q23q26),add(7)(q31),del(11)(q13),
14,+mar mar ¼ ?der(1) i(1)(q10)add(1)(q32)
[18]/92, idem x 2 [2]
Unknown 46, XX,del(6)(q23q26),
t(7;?)(q34;?),del(11)(q13),14,+mar
mar ¼ ?der(1) i(1)(q10)add(1)(q32) [18]/92,
idem x 2 [2]
6 6 M 46,XY,del(7)(q21),?inv(14)(q11q32) [14]/46,XY [6] Unknown 46,XY,t(7;?)(q34;?),?inv(14)(q11q32)
[14]/46,XY [6]
7 15 F 46,XX [20] RBTN2 (11p13) 46,XX, t(7;11)(q34;p13) [20]
8 10 M 46,XY [20] Unknown 46,XY, t(7;?)(q34;?) [20]
9 9 F 46,XX,del(7)(q34),t(10;14)(q22;q32) [11] RBTN1 (11p15) 46,XX,t(7;11)(q34;p15),t(10;14)(q22;q32) [11]
10 9 M 46,XY,t(8;14)(q24;q11) [8]/46,XY [9] RBTN1 (11p15) 46,XY,t(8;14)(q24;q11), t(7;11)(q34;p15)
[8]/46,XY [9]
11 26 M 46,XY[20] Unknown 46,XY, t(7;?)(q34;?) [20]
12 15 M 47,XY,t(7;9)(q34;q34),+20 [2]/47,
idem, add(11)(q24) [9]
TAN1 (9q34) 47,XY,t(7;9)(q34;q34),+20 [2]/47, idem,
add(11)(q24) [9]
13 30 M 46–47,XY,+mar1, +mar2, [cp5] Unknown 46–47,XY, t(7;?)(q34;?), +mar1, [cp5]
14 23 M 42–48,XY,t(3;11)(p12;p15),t(7;10)(q35;q24),
t(8;10)(q21;q?24),
+11, +12 [5]/46,XY [4]
HOX11 (10q24) 42–48,XY,t(3;11)(p12;p15),t(7;10)(q35;q24),
t(8;10)(q21;q?24), +11, +12 [5]/46,XY [4]
15 35 F 46,XX [4] failure HOXA (7p15) 46,XX, inv(7)(p15q34) [4]
16 27 F 46, XX, add(5)(q31) [11]/ 46, XX [9] HOXA (7p15) 46, XX, add(5)(q31), inv(7)(p15q34) [11]/
46, XX [9]
17 15 M 46,XY [20] HOXA (7p15) 46,XY, inv(7)(p15q34) [20]
18 34 M 46,XY [20] HOXA (7p15) 46,XY, inv(7)(p15q34) [20]




20 35 M 46, XY, t(9;20)(p21;q12), t(10;14)(q24;q11),
del(12)(p12) [13]/46, XY [12]
Negative
21 26 M 46,XY,t(6;11)(q21–22;p15),add(12)(p13)
[17]/46,XY [3]
Negative
22 35 M 46, XY [20] Negative
23 27 M 47, XY, t(7;14)(p12;q24), del(9)(q21q31),
+10 [16]/46, XY [4]
Negative
24 35 M 46, XY [25] Negative
25 24 M 46, XY [25] Negative
26 45 M 47, XY, +8 [2]/ 46, XY[20] Negative
27 5 M 47,XY,del(6)(q12),+8, del(10)(q24)[5]/ 46,XY [18] Negative 47,XY,del(6)(q12),+8, del(10)(q24), t(5;14)
(q35;q32)* [5]/ 46,XY [18]
28 9 M 46,XY [20] Negative
29 9 M 46,XY [20] Negative
30 3 M 46,XY,add(19)(p13.3),del(6)(q15q24) [6]/ 46,XY [13] Negative
31 15 M 46,XY,add(14)(q32) [9]/46,XY [18] Negative
32 16 F 46,XX,del(1)(q32),del(5)(q22q34),7,+mar [5]/46,XX [7] Negative
aIncluding M-FISH analysis.
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Fluorescence in situ hybridization (FISH)
Cytogenetic cell suspensions (methanol/acetic acid fixed cells)
or unstained slides were available for all 94 patients. For FISH
the following TCRb (7q34) and HOXA (7p15) flanking BAC
clones were selected: RP11-1220K2 (located centromeric to
TCRb) and RP11-556I13 (located telomeric to TCRb); RP1-
167F23 (containing telomeric HOXA genes HOXA1, HOXA2
and part of HOXA3) and RP5-1103I5 (located centromeric to
HOXA); RP11-1036C18, RP11-163M21, RP11-1132K14 and
RP11-1025G19 clones represent a contig spanning the entire
HOXA gene cluster (Figure 2). For further delineation of the
TCRb breakpoint, following gene covering clones were selected:
RP11-785K24 (centromeric) and RP11-701D14 (telomeric)
(Figure 3).
RPCI-11 (Human BAC Library) clones were provided by the
Welcome Trust Sanger Institute (Cambridge, UK) and Invitrogen
(Paisley, Scotland). Clone DNA isolation, labeling and FISH
were performed as previously described,12 using biotin-16-
dUTP and digoxigenin-11-dUTP (Roche Diagnostics Belgium,
Vilvoorde, Belgium) as haptens.
Disruption of the TCRb locus was assessed by dual color FISH
with TCRb flanking probes (RP11-1220K2 and RP11-556I13).
Cases carrying TCRb chromosomal rearrangement (identified by
a split signal of the flanking probes) were further analyzed to
confirm the presumed TCRb partner genes using flanking probes
for the respective partner loci (RBTN1 on 11p15, RBTN2 on
11p13, HOX11 on 10q24, TAN1 on 9q34, TAL1(SCL) on 1p32).
For those cases, which showed inversion of the distal TCRb
flanking probe to 7p, dual color FISH using HOXA flanking
probes was performed.
Hybridization signals were evaluated by two independent
observers and interpreted at the interphase (100 nuclei) and
metaphase level (when available).
RNA isolation, cDNA synthesis and quantitative
real-time RT-PCR
Patients were selected retrospectively on the basis of the
availability of frozen material at diagnosis. All human samples
were obtained according to the guidelines of the local ethical
committees. These included 13 TCRb positive cases including
five inv(7) positive and 13 TCRb negative cases. Cells obtained
from total child thymus (CT), and purified CD34þ thymocytes
(CD34þ T) were used as a reference for HOX gene expression
in normal developing T-cells.13 RNA was isolated using Trizol
(Invitrogen, Merelbeke, Belgium) and RNeasy Mini Kit (Qiagen,
Hilden, Germany) according to the manufacturer’s instructions.
DNase treatment, cDNA synthesis, primer design and SYBR
Green I quantitative real-time RT-PCR were performed as
previously described.14 Reactions were performed on an ABI
Prism 5700 Sequence Detector (Applied Biosystems, Foster City,
CA, USA). Real-time quantitative PCR data analysis and
expression normalization were performed using three internal
control genes (RPL13A, UBC, YWHAZ), as described15 and
correlated to the mean expression level of each gene. Primers for
HOXA1, HOXA4, HOXA5, HOXA7, HOXA11 were designed
according to Thompson et al.16 Primers for the other HOXA
genes (HOXA2, HOXA3, HOXA6, HOXA9, HOXA10,
HOXA13) and for HOXB3 and HOXC4 expression analysis
were designed and developed according to Wang et al17 at the
Primer Bank. Primer sequences for the tested genes are
deposited in RTPrimerDB, a public database for real-time PCR
primers (http://medgen.ugent.be/rtprimerdb) (RTPrimerDB).18
Data analysis
Statistical analysis was performed using SPSS Software (SPSS
Inc., Chicago, IL, USA) version 12.0. The nonparametric Mann–
Whitney U test (two-tailed) was used to evaluate the signifi-
cance of difference in mean expression levels between the
patients subgroups (inv(7) positive vs inv(7) negative patients).
The Fisher exact test was used to evaluate the relationship between
the specific immunophenotype and the presence of the inv(7).
Results
Frequency of chromosomal rearrangements affecting
the TCRb locus in T-ALL
A previously conducted M-FISH analysis in one T-ALL patient
(case no. 1) with a known t(1;14)(p32;q11) and TAL1(SCL)
overexpression, uncovered a cryptic translocation
t(7;11)(q34;q24) affecting the TCRb locus. No known T-cell
oncogene is located on distal 11q and breakpoint analysis is
currently ongoing. FISH screening for TCRb chromosomal
rearrangements in a large series of 93 T-ALLs yielded split
signals for the TCRb locus in 18 cases, which brings the total of
detected TCRb alterations to 20% (19/94). In six of these 19
cases, the distal probe for TCRb was translocated to recurrent
TCRb partner genes: TAL1 (case no. 2), RBTN2 (case no. 7),
RBTN1 (cases no. 9–10), TAN1 (case no. 12), HOX11 (case no.
14) as confirmed by FISH with the appropriate probes (Table 1).
In eight of the 19 cases showing TCRb rearrangement,
involvement of known partner genes was excluded. Interest-
ingly, in five other cases with split signals for the TCRb flanking
probes, the telomeric BAC clone for TCRb moved to the distal
end of the short arm of chromosome 7, thus revealing the
presence of a pericentric inversion with an unknown partner
gene (Figure 1a).
Biological characteristics, immunophenotyping and
cytogenetics
Biological characteristics for all TCRb positive cases (cases no.
1–19) and selected TCRb negative T-ALLs (case no. 20–32) are
summarized in Table 1. TCRb positive cases with inv(7), aged
15–49 years (median 32 years), showed an M/F ratio: 1.5:1.0.
TCRb positive cases without inv(7) showed a lower age of onset
compared to inv(7) positive cases: median 16.6 years (range 4–
45 years) and a pronounced male predominance (M/F ratio
3.6:1.0). Compared to inv(7) positive cases, TCRb negative cases
also showed a lower age of onset with a median of 21.8 years
(range 3–45 years) and a striking male predominance (M/F ratio
12:1).
Immunophenotypic findings from all but two cases are listed
in Table 2. Inv(7) positive cases were classified as either T3
(n¼ 1) or T4 (n¼ 4) T-ALL immunophenotypes but with a
distinct pattern of CD2 and CD8 negativity and CD1a, CD4,
CD5, CD7 and CD10 positivity. Four inv(7) positive cases were
analyzed for CD13 and CD33 expression and were found to be
negative.
Cytogenetic analysis showed abnormal karyotypes in 11 out
of 19 TCRb positive cases (Table 1). Translocations affecting the
7q34 locus were detected upon banding analysis in three of 19
cases and partial deletions of chromosome 7q or 7p in three
cases; one case showed additional material on 7q. Altoge-
ther, TCRb genomic rearrangement was unsuspected from
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cytogenetic analysis in 16/19 cases, partly due to inferior quality
of metaphase chromosomes in T-ALL. Details on cytogenetic
findings for all 94 cases including additional FISH analysis for
the other TCR loci will be reported elsewhere (Cauwelier et al,
in preparation).
Inv(7)(p15q34) is a new recurrent rearrangement in T-ALL
Since the HOXA gene cluster is known to be involved in normal
human T-cell development,13 this locus was considered as
candidate partner gene for rearrangement with the TCRb locus.
Therefore, dual color hybridization was performed on the inv(7)
positive cases using probes flanking the HOXA gene cluster
located at 7p15 (RP1-167F23 telomeric and RP5-1103I5
centromeric clones). In all five inv(7) positive cases, a split for
the HOXA flanking probes was observed, with the telomeric
clone being inverted to distal 7q (Figure 1b). To confirm these
results, we combined the centromeric flanking TCRb probe
RP11-1220K2 with the telomeric HOXA flanking probe RP1-
167F23, which yielded the expected fusion signals on the
inverted chromosome 7 in metaphases as well as in interphase
nuclei (Figure 1c).
Figure 1 Dual colour FISH results using (a) TCRb flanking probes RP11-1220K2 (green) and RP11-556I13 (red) demonstrating disruption of the
TCRb locus due to the inv(7) (case no. 18); (b) HOXA flanking centromeric probe RP5-1103I5 (green) with the telomeric and partly covering probe
RP1-167F23 (red) demonstrating disruption of the HOXA gene cluster due to the inv(7) (case no. 18); (c) centromeric flanking TCRb probe RP11-
1220K2 (green) with the telomeric HOXA flanking probe RP1-167F23 (red), which yielded the expected fusion signals on the inverted
chromosome 7 in interphase nuclei (case no. 17); (d) HOXA covering probes RP11-1132K14 (red) and RP11-1025G19 (green) revealing two fusion
signals and an extra red signal (case no. 16); (e) HOXA covering probes RP11-163M21(red) and RP11-1025G19 (green) yielding one fusion and
one split signal (case no. 16); (f) HOXA covering probes RP11-1036C19(red) and RP11-1025G16(green) yielding one fusion and one split
signal(case no. 16); (g) TCRb covering clones RP11-785K24 (red) and RP11-701D14 (green) gave the expected split signals in inv(7) (case no. 17).
Table 2 Immunophenotype of 30 T-ALL patients
Case no. 1 2 4 5 6 7 8 9 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32
CD34 60 2 0 0 1 0 0 54 nd 0 0 56 3 0 0 0 nd 0 0 0 88 1 0 0 3 0 3 31 0 82
cyCD3 90 99 99 nd 99 49 82 100 nd 95 nd 92 98 94 86 nd nd 24 91 98 90 59 99 98 76 99 nd 89 88 37
CD2 86 99 100 73 99 96 50 91 0 100 100 79 2 6 0 26w 9 96 99 17 1 97 99 99 75 0 nd 92 99 13
CD7 86 99 99 70 99 95 99 87 99 97 97 95 96 73 98 99 72 96 99 97 98 94 99 99 88 99 nd 92 98 92
CD5 88 99 99 76 15 96 97 92 96 98 99 96 96 74 91 98 94 95 99 87 86 96 99 99 43 80 nd 92 98 72
CD1a 38 24 98 56 88 0 0 5 50w 98 97 40 75 41 43 98 5 94 0 0 0 2 21 99 14w 60 nd 29 0 0
CD3m 80 95 99 98 95 23 98 96 59 1 2 1 3 73 85w 98 73 3 0 97 0 21 98 0 50w 83 3 60 96 0
CD4 22 56 99 13 1 36 95 3 50w 0 98 20 93 58 43 75 48 95 0 1 0 92 80 100 54 76 0 0 69 0
CD8 12 96 99 76 99 74 96 5 84 99 34 91 1 15 0 1 3 50 0 1 0 95 90 100 15 15 95 60 86 0
CD10 0 2 99 74 99 16 0 0 97 96 1 94 95 69 73 70 92 50 99 0 11 9 20 99 0 37 98 73 34 77
TCRgd 0 0 0 2 1 0 0 0 57w 0 nd nd 2 56 0 nd 1 0 0 87 0 1 0 0 0 45 nd 2 0 0
TCRab 0 93 49 3 1 0 0 99 0 0 nd nd 0 5 0 nd 6 3 0 3 0 20 97 99 0 0 nd 8 0 0
EGIL T4 T4 T4 T4 T4 T4 T4 T4 T4 T3 T3 T3 T3 T4 T4 T4 T4 T3 T2 T4 T2 T4 T4 T3 T4 T4 ? T4 T4 T2
TCRb + + + + + + + + + + + + + + + + +             
Data represent % of blast cells positive for the respective antigen (CD); nd: not done; w: weak.
TCRb genomic rearrangement: +: present; : absent.
Case numbers correspond to those in table n11.
Antigens are arranged in order in which they appear during T-cell differentiation.
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Further characterization of the chromosome 7p breakpoint
using three different probe combinations covering the HOXA
locus (Figure 2) yielded similar hybridization patterns in all five
inv(7) positive cases. For each of the three probe combinations
(centromeric clone RP11-1025G19 combined with more
telomeric located clones RP11-1036C18, RP11-163M21 or
RP11-1132K14, respectively) split signals of the combined
probes and complete (RP11-1036C18, RP11-163M21) or partial
(RP11-1132K14) inversion of the more telomeric located probes
were observed (Figure 1d–f). Consequently, these experiments
further confirmed the localization of the inversion 7p15 break-
point within the HOXA gene cluster and more specifically
allowed us to assign the breakpoint to the region covered by
BAC clone RP11-1132K14. Given the relative position of the
four BAC clones used in these experiments and absence of
disruption of RP11-1036C18, RP11-163M21 or RP11-1025G19,
we assume that the most probable position of the 7p15
breakpoint is within a B20 kb segment located between
HOXA5 and HOXA9 (Figure 2).
Two clones spanning most of the TCRb locus (RP11-785K24
centromeric and RP11-701D14 telomeric) revealed split signals
in all inv(7) positive cases (Figure 1g), and thus confirmed the
involvement of the TCRb gene in the inv(7) positive cases
(Figure 3). Moreover, in two inv(7) positive cases a partial
deletion of the centromeric TCRb probe in 95% (case no. 15) and
96% of cells (case no. 18) carrying the inversion was observed.
Real time quantitation of gene expression for HOXA,
HOXB3 and HOXC4 genes
Expression level measurements of all eleven members of the
HOXA gene cluster (HOXA1, HOXA2, HOXA3, HOXA4,
HOXA5, HOXA6, HOXA7, HOXA9, HOXA10, HOXA11 and
HOXA13) were performed on a total of 26 patient samples, total
CT and CD34þ purified child thymocytes (CD34þ T). Patient
samples included five inv(7) positive cases (group A), eight TCRb
positive without inv(7) (group B) and 13 TCRb negative selected
cases (group C). As no significant differences in the observed
expression pattern was noted for group B as compared to group
C (Student’s t-test: P40.05), both patient groups were joined
and inv(7) positive cases were compared to inv (7) negative
cases. A high HOXA10 and HOXA11 expression was noted for
all inv(7) positive cases whereas two inv(7) negative T-ALLs
showed similar increased levels of HOXA10 and HOXA11
transcripts (cases no. 21 and 22) (Figure 4A, B). Levels of
HOXA10 and HOXA11 expression in total CT and CD34þ
purified child thymocytes were comparable but at least 10-fold
lower than the mean expression of these genes in inv(7) positive
T-ALL samples. HOXA11 expression levels were statistically
significant increased in the inv(7) positive cases vs inv(7)
negative cases (P¼ 4.5 10E-4 and P¼ 8.8 10E-4, respec-
tively), the latter showing only marginal expression for HOXA10
and HOXA11. HOXA9 expression was slightly increased in
inv(7) positive patients as compared to the inv(7) negative
samples (P¼ 1.8 10E-3). Remarkably, in one inv(7) positive
case (no. 15), all other HOXA genes also showed increased
expression (Figure 4C(a) and (b)). Likewise, one inv(7) negative
case (no. 28) showed elevated expression for all HOXA genes
except for HOXA11 (Figure 4C(a) and (b)). For these three cases
showing elevated expression for HOXA10 and/or HOXA11
(cases no. 21, no. 22, no. 28), dual color FISH using the HOXA
flanking probes was performed to evaluate disruption of the
HOXA gene cluster but no evidence for any disruption of the
HOXA gene cluster was found.
In addition to HOXA gene expression, we tested the inv(7)
positive patients, total CT cells and CD34þ purified child
thymocytes (CD34þ T) for expression of HOXB3 and HOXC4
Figure 2 Base position of HOXA flanking (RP11-167F23 telomeric and RP11-1103I5 centromeric) and HOXA covering clones (RP11-
1132K14, RP11-1036C18, RP11-163M21 and RP11-1025G19), according to UCSC Genome Browser May 2004 Freeze.
Figure 3 Base position of TCRb flanking (RP11-1220K2 centromeric and RP11-556I13 telomeric) and covering clones (RP11-785K24, RP11-
701D14), according to UCSC Genome Browser May 2004 Freeze.
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gene expression since, according to Taghon et al,13 these were
the only homeobox genes apart from HOXA7, HOXA9,
HOXA10 and HOXA11 that were expressed at all major stages
of human thymopoiesis. In comparison with child thymocytes
and CD34þ purified child thymocytes, HOXB3 was only
weakly expressed in the inv(7) positive patients whereas HOXC4
expression was clearly detected in all inv(7) positive patients
and slightly higher than expression levels of total child
thymocytes and CD34 purified child thymocytes (Figure 5).
Discussion
In this study, we describe a new recurrent chromosomal
alteration, a pericentric inversion of chromosome 7,
inv(7)(p15q34), in five patients with T-ALL leading to disruption
of the HOXA gene cluster and juxtaposition to sequences within
the TCRb locus. As a consequence of this rearrangement,
increased HOXA10 and HOXA11 expression was evident in all
inv(7)(p15q34) positive cases as compared to most inv(7)
negative T-ALLs.
A number of findings support our assumption that this
inv(7)(p15q34) indeed represents a new recurrent chromosomal
abnormality in T-ALL. First of all, FISH results with BAC clones
covering the HOXA gene cluster at 7p15 were similar in all
cases and were in keeping with a breakpoint cluster within the
B107 kb genomic region containing all HOXA genes, most
probably distal to HOXA5 and proximal to HOXA10. Second,
gene expression analysis showed consistent increased expres-
sion of HOXA10 and HOXA11 in all inv(7) positive cases.
Thirdly, all inv(7) positive T-ALLs were classified as mature T-
ALLs (T3–4 group according to the EGIL recommendations10)
but with characteristic CD2 negative CD4 positive, CD8
negative blast cells.
The present study was initially triggered by the finding of a
cryptic t(7;11)(q34;q24) in an M-FISH study of childhood ALLs
with complex karyotypic rearrangements. Based upon this
observation, we anticipated that the distal chromosomal
localization of the TCRb locus might also predispose to the
formation of other undetected rearrangements, which indeed
turned out to be the case as demonstrated by the finding of the
recurrent inv(7)(p15q34). In addition to this new discovery, the
finding of chromosomal rearrangements affecting the TCRb
locus in as much as 20% in an unselected group of T-ALLs is in
itself remarkable. Although the study by Gesk et al8 showed a
relatively high proportion of TCRb rearrangements in a series of
T-ALLs with cytogenetically detectable rearrangements affecting
Figure 4 (A) Geometric averages of normalized expression of
HOXA10 in inv(7) positive T-ALL cases (white boxes), inv(7) negative
T-ALL cases (black boxes), total child thymocytes (CT) and CD34þ
sorted stem cells (CD34þT). (B) Geometric averages of normalized
expression of HOXA11 in inv(7) positive T-ALL cases (white boxes),
inv(7) negative T-ALL cases (black boxes), total child thymocytes (CT)
and CD34þ sorted stem cells (CD34þT). (C (a and b)) Global
overview of normalized expression of all class I HOX genes tested in
inv(7) positive T-ALLs (cases no. 15–19), inv(7) negative T-ALLs (cases
no. 2–11 and no. 20–32) and total child thymocytes (CT).
Figure 5 Geometric averages of normalized expression of HOXB3
and HOXC4 in inv(7) positive T-ALL cases (no. 15–19), total child
thymocytes (CT) and CD34þ sorted stem cells (CD34þ T).
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the TCR loci, no systematic study on unselected cases
investigating TCRb rearrangements has been reported thus far.
The high percentage of TCRb rearrangements is only partly
explained by the presence of the five inv(7) cases. Indeed, for 8/
19 TCRb positive cases, FISH screening for known TCRb
partners was negative and further testing for partner identifica-
tion is currently ongoing. In addition, some chromosomal
disruptions of the TCRb locus were found in patients with
apparent normal karyotypes and representing partly cryptic
rearrangements with known T-cell oncogenes such as RBTN2
and RBTN1 with subtelomeric localization.
Homeobox genes are a particular class of transcription factors
that play an important role in regulating aspects of morphogen-
esis and cell differentiation during normal embryonic develop-
ment. Class I HOX genes are located in tightly linked physical
clusters, whereas class II HOX genes are dispersed throughout
the genome. In humans, a total of 39 class I HOX genes are
located in four distinct gene clusters on 7p15.3 (HOXA),
17q21.3 (HOXB), 12q13.3 (HOXC) and 2q31.1 (HOXD).19
They encode a complex network of transcription regulatory
proteins whose precise targets remain poorly understood. HOX
genes were shown to play a significant role not only in
regulating body formation but also in organization and
regulation of hematopoiesis20 and leukemogenesis.21–23 Direct
effects of class I HOX gene function in hematopoiesis have been
shown in various studies where HOX gene expression has been
modulated by antisense oligonucleotides,24,25 gene disruption
by homologous recombination26,27 or by overexpression stu-
dies.28–31 In brief, forced expression of HOXA10 in murine31,32
and cord blood28,29 hematopoietic stem cells resulted in
increased proliferation and impaired myeloid differentiation
besides a profound reduction in B and T cell differentiation.
HOXA9 overexpression studies showed similar effects in
myeloid lineages but without effect on T lymphoid develop-
ment.33 Both overexpression studies of HOXA10 and HOXA9
however failed to produce any lymphoid neoplasms. In myeloid
leukemia, several class I HOX genes have been implicated
predominantly due to formation of fusion transcripts with
NUP98.34 A role for class I homeobox genes in T-ALL was first
suggested by Ferrando et al,35 who demonstrated consistently
increased expression levels of a subset of HOX genes (HOXA9,
HOXA10, HOXC6 and MEIS1) in MLL rearranged T- and B-ALL,
while myeloid lineage genes were only expressed in MLL
rearranged B-ALL and not in T-ALL cases. These findings
suggested HOX gene deregulation rather than myeloid gene
deregulation being the key factor in leukaemic transformation
mediated by MLL fusion proteins.35 Further support for a crucial
role of HOXA genes came from a study of HOXA gene
expression in developing thymocytes13 where high HOXA10
expression was found in the earliest T-cell precursors in human
thymus, which showed subsequent downregulation in CD4 and
CD8 single positive mature thymocytes. This observation
suggested a role for HOXA10 in T-cell maturation, which was
in keeping with their previous studies that showed impairment
of final T-cell differentiation upon enforced HOXA10 expression
in cord blood cells.29 In contrast to HOXA genes, expression of
the other HOX cluster genes was less prominent or absent
except for HOXB3 and HOXC4. HOXA11 was expressed at all
major stages of T-cell development also underlining the putative
important role of this particular HOX gene in thymocyte
maturation. Taken together, the present findings and published
data on HOXA expression in T-cell precursors and maturing
thymocytes strongly suggest that the HOXA gene cluster and
HOXA10 and HOXA11 genes, in particular, are of crucial
importance in normal T-cell development.
In contrast to class I homeobox genes, two particular class II
homeobox genes has been extensively studied in T-ALL, that is
HOX11, initially discovered through the t(10;14)(q24;q11),36
and HOX11L2 more recently shown to be implicated in the
cryptic t(5;14)(q35;q32).37
Chromosomal rearrangements disrupting HOX gene clusters
might also shed light onto the mechanisms controlling HOX
gene expression, that is, locally cis-acting control sequences,
global enhancer sequences located outside the gene clus-
ters.38,39 Here, we propose two possible oncogenetic mechan-
isms resulting from the inv(7). First, the disruption of the HOXA
gene cluster could interfere with the normal scheduled program
of sequential up and downregulation following the 30 to 50
localization of the HOXA genes, that is, 30 region HOXA genes
being expressed in the more primitive cells and 50 genes in more
differentiated cells. The physical disruption of the cluster could
therefore block downregulation of HOXA10 and HOXA11
required in order to allow the cells to complete their further
differentiation and maturation. The second and more classical
hypothesis is that enhancers embedded within the TCRb locus
lead to sustained high expression levels of HOXA10 and
HOXA11. Based upon the 10-fold higher expression levels
observed for HOXA10 and HOXA11 in the inv(7) positive cases
as compared to normal developing thymocytes, we favor the
latter hypothesis.
Immunophenotypically, the five inv(7) patients showed a
distinct pattern of CD2 negativity and CD4 single positivity
within the T3–4 subgroup of T-ALLs. Obviously, lack of CD2
expression on their leukaemic blasts is the most striking feature
as this pan T-cell marker is present on the leukaemic blasts of
85% of T-ALL.40 CD4 single positivity is another intriguing
finding within the T3–4 group as most cases either show CD4/
CD8 double positivity or CD8 single positivity. Taken together,
the phenotypic combination of CD2, CD4þ and CD8
showed significant correlation with the presence of the inv(7)
genomic rearrangement (P¼ 5 10E-5).
In addition to the inv(7)(p15q34) positive cases, our study
indicates that other mechanisms can lead to abnormal HOXA
gene expression as two inv(7) negative cases also showed an
elevated HOXA10 and HOXA11 expression. Moreover, a third
case was noted, which like one of the inv(7) positive cases,
showed upregulated expression of all HOXA genes. This
observation is intriguing and somewhat reminiscent to the
observed enhanced expression of certain T-cell oncogenes
(HOX11, LYL1, TAL1, LMO1 and LMO2) in the absence of any
detectable chromosomal rearrangement affecting these loci.41
Further study of these remarkable cases might increase our
understanding of the mechanisms governing the tight control of
expression of these developmentally important genes.
In conclusion, the present report describes a new recurrent
cryptic chromosomal inversion inv(7)(p15q34) in T-ALL,which
leads to elevated expression of HOXA10 and HOXA11 in five
cases and increased expression of all HOXA genes in one case
and seems to delineate a specific subset of CD2 negative CD4
single positive T-ALLs. This observation for the second time
implicates class I HOXA genes, and in particular HOXA10 and
HOXA11, in T-cell oncogenesis and strongly supports the
previously proposed role for HOXA genes in thymocyte
development. We are currently collecting additional cases of
inv(7) patients in order to determine in more detail the clinical
and biological profile of this patient subgroup and, most
importantly, in order to assess the prognostic importance of
inv(7)(p15q34) within a large cohort of uniformly treated
patients. Finally, we anticipate that this study might trigger a
search for compounds interfering with T-cell differentiation
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pathways controlled by HOXA genes and will also stimulate
new investigations focused at determining the role of HOXA
genes in T-cell development.
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